# US 2024/0124524 A1 · Agonist of Tacr2

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0124524 A1
- Document ID: US20240124524A1
- Status: Published application
- Kind: A1
- Application number: 17/768,525
- Filed: 2019-10-17
- Published: 2024-04-18
- Earliest claimed: 2019-10-17
- Assignees: University of Copenhagen
- Applicants: University of Copenhagen
- Inventors: Zachary Gerhart-Hines; Jakob Bondo Hansen; Thue W. Schwartz
- Web page: https://patentgrep.com/patent/US20240124524A1

## CPC

- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- C07K 7/22: {Tachykinins, e.g.} Eledoisins {, Substance P}; Related peptides
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to agonists of Tacr2, such as peptides agonist of Tacr2 and methods of using the same for treatment of insulin resistance, obesity and/or diabetes. The disclosure also relates to use of said agonists of Tacr2 for enhancement of energy consumption in an individual.

## Claims

### Claim 1

An agonist of Tacr2 or a pharmaceutically acceptable salt thereof for use in treatment of insulin resistance, diabetes and/or obesity in an individual in need thereof.

### Claim 2

An agonist of Tacr2 or a pharmaceutically acceptable salt thereof for use in a method of inducing weight loss in an individual in need thereof.

### Claim 3

The agonist according to any one of the preceding claims, wherein the agonist comprises or consists of a peptide.

### Claim 4

The agonist according to any one of the preceding claims, wherein the agonist consists of a peptide optionally linked to a conjugated moiety.

### Claim 5

The agonist of any one of the preceding claims, wherein the agonist or the peptide comprises or consist of a peptide of sequence X6X1FX2X3X4X5and wherein
X6=aspartic acid (E) or glutamic acid (D);
X1=serine (S) or lysine (K);
X2=valine (V) or tryptophan (W);
X3=glycine (G), β-alanine (β-ala);
X4=methyl-leucine (Me-Leu), L, γ-lactam-leucine (γ-lactam-Leu);
X5=norleucine (Nle), methionine (M). 25 6. The agonist of any one of the preceding claims, wherein the agonist or the peptide comprises or consist of a peptide of sequence DX1FX2X3X4X5and wherein
X1=serine (S) or lysine (K);
X2=valine (V) or tryptophan (W);
X3=glycine (G), β-alanine (β-ala);
X4=methyl-leucine (Me-Leu), L, γ-lactam-leucine (γ-lactam-Leu);
X5=norleucine (Nle), methionine (M).

### Claim 7

The agonist of any one of the preceding claims, wherein the agonist or the peptide comprises or consists of Neurokinin A or a functional analogue thereof.

### Claim 8 (depends on 4, 5, 6, 7)

The agonist of any one of claims 4 to 7, wherein the peptide consists of at least 7 and at most 130 amino acid residues.

### Claim 9 (depends on 4, 5, 6, 7)

The agonist of any one of claims 4 to 7, wherein the peptide consists of at least 10 and at most 130 amino acid residues.

### Claim 10 (depends on 4, 5, 6, 7, 8, 9)

The agonist of any one of claims 4 to 9, wherein the peptide comprises a precursor protein of Neurokinin A of SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14 or SEQ ID NO:15 or a functional analogue thereof sharing at least 75% sequence identity.

### Claim 11 (depends on 4, 5, 6, 7, 8, 9, 10)

The agonist of any one of claims 4 to 10, wherein the peptide comprises a fragment of the precursor protein of Neurokinin A of SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14 or SEQ ID NO:15 or a functional analogue thereof sharing at least 75% sequence identity.

### Claim 12 (depends on 4, 5, 6, 7, 8, 9, 10, 11)

The agonist of any one of claims 4 to 11, wherein the peptide consists of a consecutive sequence of SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14 or SEQ ID NO:15 or a functional analogue thereof sharing at least 75% sequence identity.

### Claim 13 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12)

The agonist of any one of claims 4 to 12, wherein the peptide comprises a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27and wherein at the most 2 amino acids have been exchanged.

### Claim 14 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The agonist of any one of claims 4 to 13, wherein the peptide consists of a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27and wherein at the most 2 amino acids have been exchanged.

### Claim 15 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The peptide of any one of claims 4 to 14, wherein the peptide comprises or consists of SEQ ID NO:2.

### Claim 16

The agonist of any one of the preceding claims, wherein the peptide comprises or consists of SEQ ID NO:1.

### Claim 17

The agonist of any one of the preceding claims, wherein the peptide comprises or consists of a sequence selected from the group consisting of SEQ ID NO:21. SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26 and SEQ ID NO:27.

### Claim 18 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The agonist according to any one of claims 3 to 17, wherein said peptide contains a C-terminal amidation or an N-terminal acetylation.

### Claim 19

The agonist of any one of the preceding claims, wherein the conjugated moiety is selected from a group consisting of peptides, lipids, glycans, saccharides and PEG.

### Claim 20

The agonist of any one of the preceding claims, wherein the conjugated moiety is a saccharide, such as a mannose.

### Claim 21

The agonist of any one of the preceding claims, wherein the conjugated moiety is a mannose, and wherein said mannose is conjugated to the N-terminal amino acid of the peptide.

### Claim 22

The agonist of any one of the preceding claims, wherein the conjugated moiety is a fatty acid selected from the group consisting of Capric acid, Lauric acid, Myristic acid, Palmitic acid, Stearic acid, and Arachidic acid.

### Claim 23

The agonist of any one of the preceding claims, wherein the conjugated moiety is a fatty acid linked to an amino acid, selected from the group consisting of -Naa-Capric acid, -Naa-Lauric acid, -Naa-Myristic acid, -Naa-Palmitic acid, -Naa-Stearic acid, and -Naa-Arachidic acid, wherein -Naa- is any proteinogenic amino acid.

### Claim 24 (depends on 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The agonist of any one of the preceding claims, wherein the conjugated moiety is attached to a terminal amino acid or to a non-terminal amino acid of the peptide of any one of claims 5 to 18.

### Claim 25

The agonist of any one of the preceding claims, wherein the conjugated moiety is selected from the group consisting of -Naa-Myristic acid, -Naa-Palmitic acid, -Naa-Stearic acid, wherein -Naa- is any proteinogenic amino acid, and wherein said conjugated moiety is attached to the Lysine in position 2 of a peptide of SEQ ID NO:1.

### Claim 26

The agonist of any one of the preceding claims, wherein the conjugated moiety is selected from the group consisting of Myristic acid, Palmitic acid, Stearic acid, and wherein said conjugated moiety is attached to the N-terminal amino acid of a peptide of SEQ ID NO:1.

### Claim 27

The agonist of any one of the preceding claims, wherein the conjugated moiety is a mannose, and wherein said mannose is conjugated to the N-terminal Serine of a peptide of SEQ ID NO:21.

### Claim 28

The agonist of any one of the preceding claims, wherein the agonist has higher affinity to Tacr2 than to Tacr1.

### Claim 29

The agonist of any one of the preceding claims, wherein the diabetes is any one of type 1 diabetes, type 2 diabetes and gestational diabetes.

### Claim 30

The agonist of any one of the preceding claims, wherein said agonist reduces the blood glucose Cmin of said individual in need thereof. 30 31. The agonist of any one of the preceding claims, wherein said agonist increases the time interval between reaching the blood glucose Cmin in response to insulin and returning to pre-insulin glucose levels in said individual in need thereof.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

A pharmaceutical composition comprising an agonist of Tacr2 or a pharmaceutically acceptable salt thereof as defined in any one of claims 1 to 31 for treatment of obesity, insulin resistance and/or diabetes in an individual in need thereof.

### Claim 33

Use of an agonist of Tacr2 or a pharmaceutically acceptable salt thereof for manufacture of a medicament for treatment of insulin resistance, diabetes and/or obesity.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 3333)

The use of claim 3333, wherein the agonist is as defined in any one of claims 1 to 31.

### Claim 35 (depends on 3333)

The use of claim 3333, wherein the diabetes is any one of type 1 diabetes, type 2 diabetes and gestational diabetes.

### Claim 36

A method for treatment of insulin resistance, diabetes and/or obesity in an individual in need thereof, wherein the method comprises administering a therapeutically effective amount of an agonist of Tacr2 or a pharmaceutically acceptable salt thereof to said individual.

### Claim 37

A method for treatment of insulin resistance, diabetes and/or obesity in an individual in need thereof, wherein the method comprises enhancing activity of brown adipose tissue cells in said individual by administration of a therapeutically effective amount of an agonist of Tacr2 or a pharmaceutically acceptable salt thereof to said individual.

### Claim 38

A method for inducing weight loss in an individual in need thereof, wherein the method comprises administering a therapeutically effective amount of an agonist of Tacr2 or a pharmaceutically acceptable salt thereof to said individual.

### Claim 39

A method for inducing weight loss in an individual in need thereof, wherein the method comprises enhancing activity of brown adipose tissue cells in said individual by administration of a therapeutically effective amount of an agonist of Tacr2 or a pharmaceutically acceptable salt thereof to said individual.

### Claim 40 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method according to any one of claims 36 to 39, wherein the agonist of Tacr2 is as defined in any one of claims 2 to 42.

### Claim 41 (depends on 36, 37, 38, 39, 40)

The method of any one of claims 36 to 40, wherein the agonist is administered parenterally to said individual.

### Claim 42 (depends on 36, 37, 38, 39, 40, 41)

The method of any one of claims 36 to 41, further comprising binding of said peptide agonist to said Tacr2.

### Claim 43 (depends on 36, 37, 38, 39, 40, 41, 42)

The method of any one of claims 36 to 42, further comprising increasing basal oxygen consumption rate and/or norepinephrine-induced oxygen consumption rate and/or maximal oxygen consumption rate in primary brown adipocytes.

### Claim 44 (depends on 36, 37, 38, 39, 40, 41, 42, 43)

The method of any one of claims 36 to 43, further comprising increasing the absorption of glucose in brown and beige adipocytes.

### Claim 45 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 36 to 44, further comprising increasing the energy consumption in brown and beige adipocytes.

### Claim 46 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The method of any one of claims 36 to 45, further comprising increasing the insulin sensitivity in said individual.

### Claim 47 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The method of any one of claims 47 to 57, further comprising stimulating the release of endogenous neurokinin A in brown and beige adipocytes.

### Claim 48 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 36 to 47, further comprising reducing the blood glucose Cmin of said individual.

### Claim 49 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The method of any one of claims 36 to 48, further comprising increasing the time interval between reaching the blood glucose Cmin in response to insulin and returning to pre-insulin glucose levels.

### Claim 50 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The method of any one of claims 36 to 49, wherein diabetes is any one of type 1 diabetes, type 2 diabetes and gestational diabetes.
